Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649

被引：0
|
作者：
Janjigian, Yelena Y.
Shitara, Kohei
Moehler, Markus H.
Garrido, Marcelo
Gallardo, Carlos
Shen, Lin
Yamaguchi, Kensei
Wyrwicz, Lucjan
Skoczylas, Tomasz
Bragagnoli, Arinilda Silva Campos
Liu, Tianshu
Tehfe, Mustapha
Elimova, Elena
Maya, Ricardo Elias Bruges
Cleary, James M.
Karamouzis, Michalis
Soleymani, Samira
Lei, Ming
Amaya-Chanaga, Carlos
Ajani, Jaffer A.
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[3] Johannes Gutenberg Univ Clin, Mainz, Germany
[4] Pontificia Univ Catolica, Clin San Carlos Apoquindo, Santiago, Chile
[5] Fdn Arturo Lopez Perez, Providencia, Chile
[6] Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Dept Gastrointestinal Oncol, Minist Educ, Beijing, Peoples R China
[7] Canc Inst Hosp JFCR, Tokyo, Japan
[8] Narodowy Instytut Onkol, Klinika Onkol & Radioterapii, Warsaw, Poland
[9] Med Univ Lublin, Klin Chirurg Ogolnej 2, Gastroenterologicznej & Nowotworow Ukladu Pokarmo, Lublin, Poland
[10] Fundacao Pio Xii Hosp Canc Barretos, Barretos, Brazil
[11] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China
[12] Ctr Hosp Univ Montreal, Oncol Ctr, Montreal, PQ, Canada
[13] Princess Margaret Canc Ctr, Toronto, ON, Canada
[14] Inst Nacl Cancerol ESE, Bogota, Colombia
[15] Dana Farber Canc Inst, Boston, MA USA
[16] Laiko Gen Hosp Athens, Athens, Greece
[17] Bristol Myers Squibb, Bristol, NJ USA
[18] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4025
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649
    Moehler, M.
    Janjigian, Y. Y.
    Shitara, K.
    Garrido, M.
    Gallardo, C.
    Shen, L.
    Yamaguchi, K.
    Wyrwicz, L.
    Skoczylas, T.
    Bragagnoli, A.
    Liu, T.
    Tehfe, M.
    Elimova, E.
    Bruges, R.
    Cleary, J. M.
    Karamouzis, M.
    Soleymani, S.
    Lei, M.
    Amaya, Chanaga C.
    Ajani, J. A.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 114 - 115
  • [2] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649.
    Janjigian, Yelena Y.
    Shitara, Kohei
    Moehler, Markus H.
    Garrido, Marcelo
    Gallardo, Carlos
    Shen, Lin
    Yamaguchi, Kensei
    Wyrwicz, Lucjan
    Skoczylas, Tomasz
    Bragagnoli, Arinilda Silva Campos
    Liu, Tianshu
    Tehfe, Mustapha
    Elimova, Elena
    Maya, Ricardo Elias Bruges
    Cleary, James M.
    Karamouzis, Michalis
    Soleymani, Samira
    Lei, Ming
    Amaya-Chanaga, Carlos
    Ajani, Jaffer A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 291 - 291
  • [3] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4-year follow-up of CheckMate 649
    Elimova, Elena
    Shitara, Kohei
    Moehler, Markus H.
    Ajani, Jaffer A.
    Shen, Lin
    Garrido, Marcelo
    Gallardo, Carlos
    Wyrwicz, Lucjan S.
    Yamaguchi, Kensei
    Cleary, James M.
    Maya, Ricardo Elias Bruges
    Karamouzis, Michalis
    Skoczylas, Tomasz
    Bragagnoli, Arinilda
    Liu, Tianshu
    Tehfe, Mustapha
    Feeney, Kynan
    Wang, Rui
    Nathani, Raheel
    Janjigian, Yelena Y.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 biomarker analyses
    Lei, Ming
    Janjigian, Yelena Y.
    Ajani, Jaffer A.
    Moehler, Markus
    Wang, Xuya
    Shen, Lin
    Garrido, Marcelo
    Gallardo, Carlos
    Yamaguchi, Kensei
    Wyrwicz, Lucjan
    Skoczylas, Tomasz
    Bragagnoli, Arinilda
    Liu, Tianshu
    Tehfe, Mustapha
    Elimova, Elena
    Li, Mingshun
    Poulart, Valerie
    Wang, Yu
    Doshi, Parul
    Shitara., Kohei
    [J]. CANCER RESEARCH, 2022, 82 (12)
  • [5] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4 year (yr) follow-up of CheckMate 649.
    Shitara, Kohei
    Moehler, Markus H.
    Ajani, Jaffer A.
    Shen, Lin
    Garrido, Marcelo
    Gallardo, Carlos
    Wyrwicz, Lucjan S.
    Yamaguchi, Kensei
    Cleary, James M.
    Elimova, Elena
    Maya, Ricardo Elias Bruges
    Karamouzis, Michalis
    Skoczylas, Tomasz
    Bragagnoli, Arinilda
    Liu, Tianshu
    Tehfe, Mustapha
    Feeney, Kynan
    Wang, Rui
    Nathani, Raheel
    Janjigian, Yelena Y.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 306 - 306
  • [6] Nivolumab (NIVO) plus chemotherapy (Chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 study
    Janjigian, Y. Y.
    Ajani, J. A.
    Moehler, M.
    Garrido, M.
    Gallardo, C.
    Shen, L.
    Yamaguchi, K.
    Wyrwicz, L.
    Skoczylas, T.
    Bragagnoli, A.
    Liu, T.
    Tehfe, M.
    Elimova, E.
    Li, M.
    Poulart, V.
    Lei, M.
    Kondo, K.
    Shitara, K.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S1329 - S1330
  • [7] Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study
    Moehler, M.
    Shitara, K.
    Garrido, M.
    Salman, P.
    Shen, L.
    Wyrwicz, L.
    Yamaguchi, K.
    Skoczylas, T.
    Campos Bragagnoli, A.
    Liu, T.
    Schenker, M.
    Yanez, P.
    Tehfe, M.
    Poulart, V.
    Cullen, D.
    Lei, M.
    Kondo, K.
    Li, M.
    Ajani, J. A.
    Janjigian, Y. Y.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S1191 - S1191
  • [8] First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): expanded efficacy and safety data from CheckMate 649
    Moehler, M.
    Shitara, K.
    Garrido, M.
    Salman, P.
    Shen, L.
    Wyrwicz, L.
    Yamaguchi, K.
    Skoczylas, T.
    Bragagnoli, Campos A.
    Liu, T.
    Schenker, M.
    Yanez, P.
    Tehfe, M.
    Li, M.
    Cullen, D.
    Memaj, A.
    Lei, M.
    Xiao, H.
    Janjigian, Y. Y.
    Ajani, J. A.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 79 - 80
  • [9] First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis with 3-year follow-up.
    Shen, Lin
    Bai, Yuxian
    Lin, Xiaoyan
    Li, Wei
    Wang, Jufeng
    Zhang, Xiaochun
    Pan, Hongming
    Bai, Chunmei
    Bai, Li
    Cheng, Ying
    Zhang, Jingdong
    Zhong, Haijun
    Ba, Yi
    Hu, Wenwei
    Xu, Rui-Hua
    Guo, Weijian
    Qin, Shukui
    Wang, Rui
    Sullivan, Kendall
    Liu, Tianshu
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 353 - 353
  • [10] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/ gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Additional analyses from 4year (y) follow-up (FU) of CheckMate 649
    Wyrwicz, L. S.
    Shitara, K.
    Moehler, M.
    Ajani, J. A.
    Shen, L.
    Garrido, M.
    Gallardo Araneda, C. E.
    Yamaguchi, K.
    Cleary, J.
    Elimova, E.
    Bruges Maya, R.
    Karamouzis, M. V.
    Skoczylas, T.
    Bragagnoli, A. C.
    Liu, T.
    Tehfe, M.
    Feeney, K.
    Wang, R.
    Zhang, J.
    Janjigian, Y. Y.
    [J]. ANNALS OF ONCOLOGY, 2024, 35 : S169 - S170
12345